{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:54:00Z","timestamp":1763571240982},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiotensin-converting enzyme 2 (ACE2) protects against organ damage in hypertension and cardiovascular diseases by counter regulating the renin-angiotensin system (RAS). ACE2 is also the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on the claim that RAS inhibitors (RASIs) cause ACE2 overexpression in some animal experiments, concerns have arisen that RASIs may aggravate SARS-CoV-2 infection and coronavirus disease-2019 severity in RASI-treated patients. To achieve a comprehensive review, a systematic search of MEDLINE\/PubMed was conducted regarding the effects of RASIs on tissue ACE2 mRNA\/protein expression in healthy animals and animal models of human diseases. We identified 88 eligible articles involving 168 experiments in the heart, kidneys, lungs, and other organs. Three of 38 experiments involving healthy animals showed ACE2 expression greater than twice that of the control (overexpression). Among 102 disease models (130 experiments), baseline ACE2 was overexpressed in 16 models (18 experiments) and less than half the control level (repression) in 28 models (40 experiments). In 72 experiments, RASIs did not change ACE2 levels from the baseline levels of disease models. RASIs caused ACE2 overexpression compared to control levels in seven experiments, some of which were unsupported by other experiments under similar conditions. In 36 experiments, RASIs reversed or prevented disease-induced ACE2 repression, yielding no or marginal changes. Therefore, ACE2 overexpression appears to be a rare rather than common consequence of RASI treatment in healthy animals and disease models. Future studies should clarify the pathophysiological significance of RASI-induced reversal or prevention of ACE2 repression in disease models.<\/jats:p>","DOI":"10.1038\/s41440-021-00641-1","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T04:42:26Z","timestamp":1615351346000},"page":"955-968","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies"],"prefix":"10.1038","volume":"44","author":[{"given":"Hisashi","family":"Kai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Niiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Okina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"641_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev. 2018;98:505\u201353.","journal-title":"Physiol Rev"},{"key":"641_CR2","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin converting enzyme 2- SARS-CoV-2 receptor and regulator of the renin angiotensin system. Circ Res. 2020;126:1456\u201374.","journal-title":"Circ Res"},{"key":"641_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","volume":"43","author":"H Kai","year":"2020","unstructured":"Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors\u2014lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648\u201354.","journal-title":"Hypertens Res"},{"key":"641_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41440-020-0515-0","volume":"43","author":"S Shibata","year":"2020","unstructured":"Shibata S, Arima H, Asayama K, Hoshide S, Ichikawa A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hyperension Task Force on COVID-19. Hypertens Res. 2020;43:1028\u201346.","journal-title":"Hypertens Res"},{"key":"641_CR5","doi-asserted-by":"publisher","first-page":"H2281","DOI":"10.1152\/ajpheart.00618.2005","volume":"289","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281\u201390.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"641_CR6","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1016\/j.jacc.2020.04.028","volume":"75","author":"A Brojakowska","year":"2020","unstructured":"Brojakowska A, Narula J, Shimony R, Bander J. Clinical implications of SARS-Cov2 interaction with renin angiotensin system. J Am Coll Cardiol. 2020;75:3085\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"641_CR7","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.","journal-title":"Lancet Respir Med"},{"key":"641_CR8","doi-asserted-by":"publisher","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","volume":"9","author":"R Sommerstein","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, Gr\u00e4ni C. Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9:e016509.","journal-title":"J Am Heart Assoc"},{"key":"641_CR9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","volume":"116","author":"R Kreutz","year":"2020","unstructured":"Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury- implications for COVID-19. Cardiovasc Res. 2020;116:1688\u201399.","journal-title":"Cardiovasc Res"},{"key":"641_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u20133.","journal-title":"Nature."},{"key":"641_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.e8.","journal-title":"Cell"},{"key":"641_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281\u201392.e6.","journal-title":"Cell."},{"key":"641_CR13","doi-asserted-by":"publisher","first-page":"H1013","DOI":"10.1152\/ajpheart.00068.2005","volume":"289","author":"M Igase","year":"2005","unstructured":"Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005;289:H1013\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"641_CR14","doi-asserted-by":"publisher","first-page":"H2166","DOI":"10.1152\/ajpheart.00061.2006","volume":"291","author":"JA Jessup","year":"2006","unstructured":"Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, et al. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic ren-2 rat. Am J Physiol Heart Circ Physiol. 2006;291:H2166\u201372.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"641_CR15","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYPERTENSIONAHA.113.02426","volume":"63","author":"K Ohshima","year":"2014","unstructured":"Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, et al. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension. 2014;63:e53\u201359.","journal-title":"Hypertension."},{"key":"641_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"641_CR17","first-page":"1","volume":"20","author":"JR Lechien","year":"2020","unstructured":"Lechien JR, Radulesco T, Calvo-Henriquez C, Chiesa-Estomba CM, Hans S, Barillari MR, et al. ACE2 & TMPRSS2 expressions in head & neck tissues: a systematic review. Head Neck Pathol. 2020;20:1\u201311.","journal-title":"Head Neck Pathol"},{"key":"641_CR18","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation."},{"key":"641_CR19","first-page":"e29","volume":"76","author":"C Wu","year":"2020","unstructured":"Wu C, Ye D, Mullick AE, Li Z, Danser AHJ, Daugherty A, et al. Effects of renin-angiotensin inhibition on ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane protease serine 2) expression: insights into COVID-19. Hypertension. 2020;76:e29\u201330.","journal-title":"Hypertension."},{"key":"641_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bcp.2017.07.022","volume":"144","author":"V Sukumaran","year":"2017","unstructured":"Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M, Pearson JT. Azilsartan ameliorates diabetic cardiomyopathy in young db\/db mice through the modulation of ACE-2\/ANG 1-7\/Mas receptor cascade. Biochem Pharmacol. 2017;144:90\u20139.","journal-title":"Biochem Pharmacol"},{"key":"641_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","volume":"48","author":"MP Ocaranza","year":"2006","unstructured":"Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48:572\u20138.","journal-title":"Hypertension."},{"key":"641_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.pharep.2016.03.002","volume":"68","author":"L Ibarra-Lara","year":"2016","unstructured":"Ibarra-Lara L, Del Valle-Mondrag\u00f3n L, Soria-Castro E, Torres-Narv\u00e1ez JC, P\u00e9rez-Severiano F, S\u00e1nchez-Aguilar M, et al. Peroxisome proliferator-activated receptor-\u03b1 stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle. Pharmacol Rep. 2016;68:692\u2013702.","journal-title":"Pharmacol Rep"},{"key":"641_CR23","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1681\/ASN.2020050667","volume":"31","author":"J Wysocki","year":"2020","unstructured":"Wysocki J, Lores E, Ye M, Soler MJ, Batlle D. Kidney and lung ACE2 expression after an ACE inhibitor or an ang II receptor blocker: Implications for COVID-19. J Am Soc Nephrol. 2020;31:1941\u20133.","journal-title":"J Am Soc Nephrol"},{"key":"641_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jash.2007.10.005","volume":"2","author":"JA Jessup","year":"2008","unstructured":"Jessup JA, Brosnihan KB, Gallagher PE, Chappell MC, Ferrario CM. Differential effect of low dose thiazides on the renin angiotensin system in genetically hypertensive and normotensive rats. J Am Soc Hypertens. 2008;2:106\u201315.","journal-title":"J Am Soc Hypertens"},{"key":"641_CR25","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1111\/j.1523-1755.2005.00675.x","volume":"68","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189\u201396.","journal-title":"Kidney Int"},{"key":"641_CR26","doi-asserted-by":"publisher","first-page":"e00398","DOI":"10.1042\/BSR20160344","volume":"36","author":"GE Callera","year":"2016","unstructured":"Callera GE, Antunes TT, Correa JW, Moorman D, Gutsol A, He Y, et al. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2\/AT2R\/Mas axis. Biosci Rep. 2016;36:e00398.","journal-title":"Biosci Rep"},{"key":"641_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1113\/expphysiol.2007.041855","volume":"93","author":"I Hamming","year":"2008","unstructured":"Hamming I, van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P, et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol. 2008;93:631\u20138.","journal-title":"Exp Physiol"},{"key":"641_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1042\/CS20090318","volume":"118","author":"E Velkoska","year":"2010","unstructured":"Velkoska E, Dean RG, Burchill L, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci. 2010;118:269\u201379.","journal-title":"Clin Sci"},{"key":"641_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1074248409351409","volume":"15","author":"D Senador","year":"2010","unstructured":"Senador D, Key M, Brosnihan KB, Irigoyen MC, Elased KM, Morris M. Cardiovascular interactions between losartan and fructose in mice. J Cardiovasc Pharmacol Ther. 2010;15:68\u201377.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"641_CR30","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2337\/db07-1212","volume":"57","author":"C Tikellis","year":"2008","unstructured":"Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental. Diabetes Diabetes. 2008;57:1018\u201325.","journal-title":"Diabetes Diabetes."},{"key":"641_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.112.191452","volume":"60","author":"M Iwai","year":"2012","unstructured":"Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension. 2012;60:137\u201344.","journal-title":"Hypertension."},{"key":"641_CR32","doi-asserted-by":"publisher","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","volume":"296","author":"MJ Soler","year":"2009","unstructured":"Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Ren Physiol. 2009;296:F398\u2013F405.","journal-title":"Am J Physiol Ren Physiol"},{"key":"641_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1470320315576256","volume":"16","author":"YM Yuan","year":"2015","unstructured":"Yuan YM, Luo L, Guo Z, Yang M, Ye RS, Luo C. Activation of renin-angiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats. J Renin Angiotensin Aldosterone Syst. 2015;16:249\u201353.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"641_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbi.2017.11.010","volume":"69","author":"M Yisireyili","year":"2018","unstructured":"Yisireyili M, Uchida Y, Yamamoto K, Nakayama T, Cheng XW, Matsushita T, et al. Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice. Brain Behav Immun. 2018;69:167\u201379.","journal-title":"Brain Behav Immun"},{"key":"641_CR35","doi-asserted-by":"publisher","first-page":"e0217030","DOI":"10.1371\/journal.pone.0217030","volume":"14","author":"IP Cano","year":"2019","unstructured":"Cano IP, Dionisio TJ, Cestari TM, Calvo AM, Colombini-Ishikiriama BL, Faria FAC, et al. Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands. PLoS ONE. 2019;14:e0217030.","journal-title":"PLoS ONE"},{"key":"641_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1161\/HYPERTENSIONAHA.116.07008","volume":"68","author":"H Li","year":"2016","unstructured":"Li H, Li M, Liu P, Wang Y, Zhang H, Li H, et al. Telmisartan ameliorates nephropathy in metabolic syndrome by reducing leptin release from perirenal adipose tissue. Hypertension. 2016;68:478\u201390.","journal-title":"Hypertension."},{"key":"641_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biopha.2017.05.062","volume":"92","author":"HM Abuohashish","year":"2017","unstructured":"Abuohashish HM, Ahmed MM, Sabry D, Khattab MM, Al-Rejaie SS. ACE-2\/Ang1-7\/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. Biomed Pharmacother. 2017;92:58\u201368.","journal-title":"Biomed Pharmacother"},{"key":"641_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2017.04.031","volume":"807","author":"HM Abuohashish","year":"2017","unstructured":"Abuohashish HM, Ahmed MM, Sabry D, Khattab MM, Al-Rejaie SS. The ACE-2\/Ang1-7\/Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade. Eur J Pharmacol. 2017;807:44\u201355.","journal-title":"Eur J Pharmacol"},{"key":"641_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/1074248419838503","volume":"24","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Ma R, Yu X, Li N, Zhao X, Yu J. AHU377+valsartan (LCZ696) modulates renin-angiotensin system (RAS) in the cardiac of female spontaneously hypertensive rats compared with valsartan. J Cardiovasc Pharmacol Ther. 2019;24:450\u20139.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"641_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.acvd.2013.01.004","volume":"106","author":"Z Yang","year":"2013","unstructured":"Yang Z, Yu X, Cheng L, Miao LY, Li HX, Han LH, et al. Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats. Arch Cardiovasc Dis. 2013;106:196\u2013201.","journal-title":"Arch Cardiovasc Dis"},{"key":"641_CR41","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1291\/hypres.29.865","volume":"29","author":"J Agata","year":"2006","unstructured":"Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res. 2006;29:865\u201374.","journal-title":"Hypertens Res"},{"key":"641_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/FJC.0000000000000374","volume":"67","author":"T Tanno","year":"2016","unstructured":"Tanno T, Tomita H, Narita I, Kinjo T, Nishizaki K, Ichikawa H, et al. Olmesartan inhibits cardiac hypertrophy in mice overexpressing renin independently of blood pressure: Its beneficial effects on ACE2\/Ang(1-7)\/Mas axis and NADPH oxidase expression. J Cardiovasc Pharmacol. 2016;67:503\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"641_CR43","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/hr.2014.49","volume":"37","author":"J Iwanami","year":"2014","unstructured":"Iwanami J, Mogi M, Tsukuda K, Wang XL, Nakaoka H, Ohshima K, et al. Role of angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas axis in the hypotensive effect of azilsartan. Hypertens Res. 2014;37:616\u201320.","journal-title":"Hypertens Res"},{"key":"641_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ace2 is mediated by tace\/adam-17: a positive feedback mechanism in the ras. J Mol Cell Cardiol. 2014;66:167\u201376.","journal-title":"J Mol Cell Cardiol"},{"key":"641_CR45","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.amjhyper.2007.05.008","volume":"20","author":"Y Takeda","year":"2007","unstructured":"Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens. 2007;20:1119\u201324.","journal-title":"Am J Hypertens"},{"key":"641_CR46","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1097\/HJH.0b013e32834bbb4d","volume":"29","author":"S Inaba","year":"2011","unstructured":"Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, et al. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens. 2011;29:2236\u201345.","journal-title":"J Hypertens"},{"key":"641_CR47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","volume":"97","author":"X Wang","year":"2016","unstructured":"Wang X, Ye Y, Gong H, Wu J, Yuan J, Wang S, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016;97:180\u201390.","journal-title":"J Mol Cell Cardiol"},{"key":"641_CR48","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.2147\/DDDT.S144807","volume":"11","author":"WW Zhang","year":"2017","unstructured":"Zhang WW, Bai F, Wang J, Zheng RH, Yang LW, James EA, et al. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor. Drug Des Devel Ther. 2017;11:3019\u201333.","journal-title":"Drug Des Devel Ther"},{"key":"641_CR49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/CS20120519","volume":"125","author":"\u00c1P Souza","year":"2013","unstructured":"Souza \u00c1P, Sobrinho DB, Almeida JF, Alves GM, Macedo LM, Porto JE, et al. Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts. Clin Sci. 2013;125:449\u201359.","journal-title":"Clin Sci"},{"key":"641_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4077\/CJP.2014.BAD268","volume":"57","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Li B, Wang B, Zhang J, Wu J, Morgan T. Alteration of cardiac ACE2\/Mas expression and cardiac remodelling in rats with aortic constriction. Chin J Physiol. 2014;57:335\u201342.","journal-title":"Chin J Physiol"},{"key":"641_CR51","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/DDDT.S213910","volume":"13","author":"RH Zheng","year":"2019","unstructured":"Zheng RH, Bai XJ, Zhang WW, Wang J, Bai F, Yan CP, et al. Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther. 2019;13:2745\u201357.","journal-title":"Drug Des Devel Ther"},{"key":"641_CR52","first-page":"1443","volume":"8","author":"B Liang","year":"2015","unstructured":"Liang B, Li Y, Han Z, Xue J, Zhang Y, Jia S, et al. ACE2-Ang (1-7) axis is induced in pressure overloaded rat model. Int J Clin Exp Pathol. 2015;8:1443\u201350.","journal-title":"Int J Clin Exp Pathol"},{"key":"641_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.mce.2011.12.010","volume":"351","author":"V Sukumaran","year":"2012","unstructured":"Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol. 2012;351:208\u201319.","journal-title":"Mol Cell Endocrinol"},{"key":"641_CR54","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.7150\/ijbs.7.1077","volume":"7","author":"V Sukumaran","year":"2011","unstructured":"Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2\/angiotensin 1-7\/mas receptor axis. Int J Biol Sci. 2011;7:1077\u201392.","journal-title":"Int J Biol Sci"},{"key":"641_CR55","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3109\/10715762.2012.684878","volume":"46","author":"V Sukumaran","year":"2012","unstructured":"Sukumaran V, Veeraveedu PT, Lakshmanan AP, Gurusamy N, Yamaguchi K, Ma M, et al. Olmesartan medoxomil treatment potently improves cardiac myosin induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 Mas receptor. Free Radic Res. 2012;46:850\u201360.","journal-title":"Free Radic Res"},{"key":"641_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.lfs.2011.11.018","volume":"90","author":"V Sukumaran","year":"2012","unstructured":"Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, et al. Telmisartan acts through the modulation of ACE-2\/ANG 1-7\/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. Life Sci. 2012;90:289\u2013300.","journal-title":"Life Sci"},{"key":"641_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.tox.2011.11.008","volume":"291","author":"S Arumugam","year":"2012","unstructured":"Arumugam S, Thandavarayan RA, Palaniyandi SS, Giridharan VV, Arozal W, Sari FR, et al. Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: Involvement of ACE2-Ang (1-7)-mas axis. Toxicology. 2012;291:139\u201345.","journal-title":"Toxicology"},{"key":"641_CR58","doi-asserted-by":"publisher","first-page":"H1351","DOI":"10.1152\/ajpheart.01186.2004","volume":"289","author":"T Karram","year":"2005","unstructured":"Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H1351\u20138.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"641_CR59","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3382\/ps.2012-02671","volume":"92","author":"XQ Hao","year":"2013","unstructured":"Hao XQ, Zhang SY, Cheng XC, Li M, Sun TW, Zhang JL, et al. Imidapril inhibits right ventricular remodeling induced by low ambient temperature in broiler chickens. Poult Sci. 2013;92:1492\u20137.","journal-title":"Poult Sci"},{"key":"641_CR60","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1042\/CS20120162","volume":"123","author":"LJ Burchill","year":"2012","unstructured":"Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin\u2013angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci. 2012;123:649\u201358.","journal-title":"Clin Sci"},{"key":"641_CR61","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/eurheartj\/ehi114","volume":"26","author":"LM Burrell","year":"2005","unstructured":"Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26:369\u201375.","journal-title":"Eur Heart J"},{"key":"641_CR62","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970\u20136.","journal-title":"Hypertension."},{"key":"641_CR63","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3892\/mmr.2017.6848","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, He W, Guo L, Zhang Y, Li H, Han S, et al. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. Mol Med Rep. 2017;16:1973\u201381.","journal-title":"Mol Med Rep"},{"key":"641_CR64","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","volume":"29","author":"P Mulder","year":"2008","unstructured":"Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29:2171\u20139.","journal-title":"Eur Heart J"},{"key":"641_CR65","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/jcmm.13406","volume":"22","author":"Y Tie","year":"2018","unstructured":"Tie Y, Zhai C, Zhang Y, Qin X, Yu F, Li H, et al. CCAAT\/enhancer-binding protein \u03b2 overexpression alleviates myocardial remodelling by regulating angiotensin-converting enzyme-2 expression in diabetes. J Cell Mol Med. 2018;22:1475\u201388.","journal-title":"J Cell Mol Med"},{"key":"641_CR66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1042\/CS20100280","volume":"120","author":"E Velkoska","year":"2011","unstructured":"Velkoska E, Dean RG, Griggs K, Burchill L, Burrell LM. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci. 2011;120:335\u201345.","journal-title":"Clin Sci"},{"key":"641_CR67","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1113\/expphysiol.2007.040386","volume":"93","author":"L Burchill","year":"2008","unstructured":"Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V, et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol. 2008;93:622\u201330.","journal-title":"Exp Physiol"},{"key":"641_CR68","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1113\/expphysiol.2011.063156","volume":"97","author":"LM Burrell","year":"2012","unstructured":"Burrell LM, Burchill L, Dean RG, Griggs K, Patel SK, Velkoska E. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Expl Physiol. 2012;97:477\u201385.","journal-title":"Expl Physiol"},{"key":"641_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1470320314568439","volume":"16","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Ma L, Wu J, Chen T. Hydronephrosis alters cardiac ACE2 and Mas receptor expression in mice. J Renin Angiotensin Aldosterone Syst. 2015;16:267\u201374.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"641_CR70","doi-asserted-by":"publisher","first-page":"24548","DOI":"10.18632\/oncotarget.15595","volume":"8","author":"H Ma","year":"2017","unstructured":"Ma H, Kong J, Wang YL, Li JL, Hei NH, Cao XR, et al. Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. Oncotarget. 2017;8:24548\u201363.","journal-title":"Oncotarget."},{"key":"641_CR71","doi-asserted-by":"publisher","first-page":"152310","DOI":"10.1016\/j.tox.2019.152310","volume":"428","author":"ZM Awwad","year":"2019","unstructured":"Awwad ZM, El-Ganainy SO, ElMallah AI, Khattab MM, El-Khatib AS. Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats. Toxicology. 2019;428:152310.","journal-title":"Toxicology."},{"key":"641_CR72","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12872-018-0875-4","volume":"18","author":"W Wang","year":"2018","unstructured":"Wang W, Song A, Zeng Y, Chen X, Zhang Y, Shi Y, et al. Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity. BMC Cardiovasc Disord. 2018;18:133.","journal-title":"BMC Cardiovasc Disord"},{"key":"641_CR73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.regpep.2013.03.005","volume":"184","author":"S Bai","year":"2013","unstructured":"Bai S, Huang ZG, Chen L, Wang JT, Ding BP. Effects of felodipine combined with puerarin on ACE2\u2013Ang (1\u20137)\u2013Mas axis in renovascular hypertensive rat. Regul Pept. 2013;184:54\u201361.","journal-title":"Regul Pept"},{"key":"641_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10157-010-0373-1","volume":"15","author":"S Fukuda","year":"2011","unstructured":"Fukuda S, Horimai C, Harada K, Wakamatsu T, Fukasawa H, Muto S, et al. Aldosterone-induced kidney injury is mediated by NF\u03baB activation. Clin Exp Nephrol. 2011;15:41\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"641_CR75","doi-asserted-by":"publisher","first-page":"F1308","DOI":"10.1152\/ajprenal.00167.2006","volume":"291","author":"AT Whaley-Connell","year":"2006","unstructured":"Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Ren Physiol. 2006;291:F1308\u201314.","journal-title":"Am J Physiol Ren Physiol"},{"key":"641_CR76","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1536\/ihj.17-582","volume":"59","author":"H Ichikawa","year":"2018","unstructured":"Ichikawa H, Narita I, Narita M, Tanno T, Yokono Y, Kimura Y, et al. Blood pressure-independent effect of olmesartan on albuminuria in mice overexpressing renin. Int Heart J. 2018;59:1445\u201353.","journal-title":"Int Heart J"},{"key":"641_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00109-015-1343-6","volume":"94","author":"D Ding","year":"2016","unstructured":"Ding D, Du Y, Qiu Z, Yan S, Chen F, Wang M, et al. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy. J Mol Med. 2016;94:207\u201318.","journal-title":"J Mol Med"},{"key":"641_CR78","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/01.HYP.0000060689.38912.CB","volume":"41","author":"C Tikellis","year":"2003","unstructured":"Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392\u201397.","journal-title":"Hypertension."},{"key":"641_CR79","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/10715762.2011.560149","volume":"45","author":"AP Lakshmanan","year":"2011","unstructured":"Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-\u03b3 agonist action. Free Radic Res. 2011;45:575\u201384.","journal-title":"Free Radic Res"},{"key":"641_CR80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.mce.2011.07.041","volume":"348","author":"AP Lakshmanan","year":"2012","unstructured":"Lakshmanan AP, Thandavarayan RA, Watanabe K, Sari FR, Meilei H, Giridharan VV, et al. Modulation of AT-1R\/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Mol Cell Endocrinol. 2012;348:104\u201311.","journal-title":"Mol Cell Endocrinol"},{"key":"641_CR81","doi-asserted-by":"publisher","first-page":"F534","DOI":"10.1152\/ajprenal.00082.2015","volume":"310","author":"M Riera","year":"2016","unstructured":"Riera M, Anguiano L, Clotet S, Roca-Ho H, Rebull M, Pascual J, et al. Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. Am J Physiol Ren Physiol. 2016;310:F534\u2013F546.","journal-title":"Am J Physiol Ren Physiol"},{"key":"641_CR82","doi-asserted-by":"publisher","first-page":"F1523","DOI":"10.1152\/ajprenal.00426.2009","volume":"298","author":"M Dilauro","year":"2010","unstructured":"Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Ren Physiol. 2010;298:F1523\u201332.","journal-title":"Am J Physiol Ren Physiol"},{"key":"641_CR83","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.3390\/ijms20153843","volume":"20","author":"SH Suh","year":"2019","unstructured":"Suh SH, Choi HS, Kim CS, Kim IJ, Ma SK, Scholey JW, et al. Olmesartan attenuates kidney fibrosis in a murine model of alport syndrome by suppressing tubular expression of TGF\u03b2. Int J Mol Sci. 2019;20:3843.","journal-title":"Int J Mol Sci"},{"key":"641_CR84","first-page":"73","volume":"32","author":"MA de Jong","year":"2017","unstructured":"de Jong MA, Mirkovic K, Mencke R, Hoenderop JG, Bindels RJ, Vervloet MG, et al. Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis. Nephrol Dial Transpl. 2017;32:73\u201380.","journal-title":"Nephrol Dial Transpl"},{"key":"641_CR85","doi-asserted-by":"publisher","first-page":"e66082","DOI":"10.1371\/journal.pone.0066082","volume":"8","author":"KD Silveira","year":"2013","unstructured":"Silveira KD, Barroso LC, Vieira AT, Cisalpino D, Lima CX, Bader M, et al. Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS ONE. 2013;8:e66082.","journal-title":"PLoS ONE"},{"key":"641_CR86","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41440-019-0271-1","volume":"42","author":"S Kidoguchi","year":"2019","unstructured":"Kidoguchi S, Sugano N, Takane K, Takahashi Y, Morisawa N, Yarita M, et al. Azilsartan causes natriuresis due to its sympatholytic action in kidney disease. Hypertens Res. 2019;42:1507\u201317.","journal-title":"Hypertens Res"},{"key":"641_CR87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12079-018-0466-2","volume":"13","author":"EL Kong","year":"2019","unstructured":"Kong EL, Zhang JM, An N, Tao Y, Yu WF, Wu FX. Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression. J Cell Commun Signal. 2019;13:17\u201326.","journal-title":"J Cell Commun Signal"},{"key":"641_CR88","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/FJC.0000000000000340","volume":"67","author":"L Mart\u00ednez-Aguilar","year":"2016","unstructured":"Mart\u00ednez-Aguilar L, Lezama-Mart\u00ednez D, Orozco-Cort\u00e9s NV, Gonz\u00e1lez-Espinosa C, Flores-Monroy J, Valencia-Hern\u00e1ndez I. Antihypertensive properties of a novel morphologic derivative (4-tert-buthyl-2,6-bis(thiomorpholine-4-ilmethyl)phenol). J Cardiovasc Pharmacol. 2016;67:246\u201351.","journal-title":"J Cardiovasc Pharmacol"},{"key":"641_CR89","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FJC.0000000000000629","volume":"72","author":"D Lezama-Martinez","year":"2018","unstructured":"Lezama-Martinez D, Flores-Monroy J, Fonseca-Coronado S, Hernandez-Campos ME, Valencia-Hernandez I, et al. Combined antihypertensive therapies that increase expression of cardioprotective biomarkers associated with the renin-angiotensin and kallikrein-kinin systems. J Cardiovasc Pharmacol. 2018;72:291\u201395.","journal-title":"J Cardiovasc Pharmacol"},{"key":"641_CR90","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/hr.2012.187","volume":"36","author":"S Takai","year":"2013","unstructured":"Takai S, Jin D, Aritomi S, Niinuma K, Miyazaki M. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertens Res. 2013;36:342\u20138.","journal-title":"Hypertens Res"},{"key":"641_CR91","doi-asserted-by":"publisher","first-page":"e38502","DOI":"10.1371\/journal.pone.0038502","volume":"7","author":"HY Jin","year":"2012","unstructured":"Jin HY, Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY, et al. ACE2 deficiency enhances angiotensin ii-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLos ONE. 2012;7:e38502.","journal-title":"PLos ONE"},{"key":"641_CR92","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.abb.2016.03.028","volume":"598","author":"Y Li","year":"2016","unstructured":"Li Y, Cai S, Wang Q, Zhou J, Hou B, Yu H, et al. Valsartan attenuates intimal hyperplasia in balloon-injured rat aortic arteries through modulating the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis. Arch Biochem Biophys. 2016;598:11\u201317.","journal-title":"Arch Biochem Biophys"},{"key":"641_CR93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1291\/hypres.31.553","volume":"31","author":"M Igase","year":"2008","unstructured":"Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res. 2008;31:553\u201359.","journal-title":"Hypertens Res"},{"key":"641_CR94","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/1470320314542829","volume":"16","author":"YH Zhang","year":"2015","unstructured":"Zhang YH, Hao QQ, Wang XY, Chen X, Wang N, Zhu L, et al. ACE2 activity was increased in atherosclerotic plaque by losartan: possible relation to anti-atherosclerosis. J Renin Angiotensin Aldosterone Syst. 2015;16:292\u2013300.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"641_CR95","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1161\/HYPERTENSIONAHA.108.123844","volume":"53","author":"H Xia","year":"2009","unstructured":"Xia H, Feng Y, Obr TD, Hickman PJ, Lazartigues E. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension. 2009;53:210\u201316.","journal-title":"Hypertension."},{"key":"641_CR96","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/HYPERTENSIONAHA.110.167650","volume":"57","author":"K Shimada","year":"2011","unstructured":"Shimada K, Kitazato KT, Kinouchi T, Yagi K, Tada Y, Satomi J, et al. Activation of estrogen receptor-\u03b1 and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats. Hypertension. 2011;57:1161\u201366.","journal-title":"Hypertension."},{"key":"641_CR97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.lfs.2014.12.004","volume":"121","author":"LH Wang","year":"2015","unstructured":"Wang LH, Dong T, Liu BB, Zhao XD, Chen JW, Murao K, et al. Contribution of the renin-angiotensin system in chronic foot-shock induced hypertension in rats. Life Sci. 2015;121:135\u201344.","journal-title":"Life Sci"},{"key":"641_CR98","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11596-019-2073-8","volume":"39","author":"BN Zhang","year":"2019","unstructured":"Zhang BN, Zhang X, Xu H, Gao XM, Zhang GZ, Zhang H, et al. Dynamic variation of RAS on silicotic fibrosis pathogenesis in rats. Curr Med Sci. 2019;39:551\u201359.","journal-title":"Curr Med Sci."},{"key":"641_CR99","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1470320312466126","volume":"15","author":"XQ Hao","year":"2014","unstructured":"Hao XQ, Zhang SY, Li M, Yang Z, Niu MF, Sun TW, et al. Imidapril provides a protective effect on pulmonary hypertension induced by low ambient temperature in broiler chickens. J Renin Angiotensin Aldosterone Syst. 2014;15:162\u201369.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"641_CR100","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fphar.2019.00708","volume":"10","author":"SHP Oliveira","year":"2019","unstructured":"Oliveira SHP, Brito VGB, Frasnelli SCT, Ribeiro BDS, Ferreira MN, Queiroz DP, et al. Aliskiren attenuates the inflammatory response and wound healing process in diabetic mice with periodontal disease. Front Pharmacol. 2019;10:708.","journal-title":"Front Pharmacol"},{"key":"641_CR101","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4254\/wjh.v11.i4.359","volume":"11","author":"F Graus-Nunes","year":"2019","unstructured":"Graus-Nunes F, Santos FO, Marinho TS, Miranda CS, Barbosa-da-Silva S, Souza-Mello V. Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model. World J Hepatol. 2019;11:359\u201369.","journal-title":"World J Hepatol"},{"key":"641_CR102","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11596-015-1463-9","volume":"35","author":"L Wu","year":"2015","unstructured":"Wu L, Zhou PQ, Xie JW, Zhu RS, Zhou SC, Wang G, et al. Effects of yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver. J Huazhong Univ Sci Technol Med Sci. 2015;35:519\u201324.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"641_CR103","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/aps.2012.115","volume":"33","author":"ET Yi","year":"2012","unstructured":"Yi ET, Liu RX, Wen Y, Yin CH. Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats. Acta Pharmacol Sin. 2012;33:1518\u201324.","journal-title":"Acta Pharmacol Sin"},{"key":"641_CR104","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1440-1681.2009.05302.x","volume":"37","author":"ML Huang","year":"2010","unstructured":"Huang ML, Li X, Meng Y, Xiao B, Ma Q, Ying SS, et al. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clin Exp Pharmacol Physiol. 2010;37:e1\u2013e6.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"641_CR105","doi-asserted-by":"publisher","first-page":"e67192","DOI":"10.1371\/journal.pone.0067192","volume":"8","author":"ED Frantz","year":"2013","unstructured":"Frantz ED, Crespo-Mascarenhas C, Barreto-Vianna AR, Aguila MB, Mandarim-de-Lacerda CA. Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice. PLoS ONE. 2013;8:e67192.","journal-title":"PLoS ONE"},{"key":"641_CR106","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/13813455.2018.1453521","volume":"125","author":"MM Sabry","year":"2019","unstructured":"Sabry MM, Mahmoud MM, Shoukry HS, Rashed L, Kamar SS, Ahmed MM. Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats. Arch Physiol Biochem. 2019;125:244\u201354.","journal-title":"Arch Physiol Biochem"},{"key":"641_CR107","unstructured":"Esler M, Esler D. COVID-19 and hypertension. Hypertens News. 2020;June:32\u201334."},{"key":"641_CR108","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"641_CR109","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441\u20138.","journal-title":"N Engl J Med"},{"key":"641_CR110","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020\u20136.","journal-title":"JAMA Cardiol."},{"key":"641_CR111","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324:168\u201377.","journal-title":"JAMA."},{"key":"641_CR112","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","volume":"43","author":"Y Matsuzawa","year":"2020","unstructured":"Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, et al. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res. 2020;43:1257\u201366.","journal-title":"Hypertens Res"},{"key":"641_CR113","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19 a randomized clinical trial. JAMA. 2021;325:254\u201364.","journal-title":"JAMA"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00641-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00641-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00641-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:20:19Z","timestamp":1628119219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00641-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00641-1","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}